TennesseeHB 1157114th General Assembly (2025-2026)House

AN ACT to amend Tennessee Code Annotated, Title 53 and Title 68, relative to relative to drug labels.

Sponsored By: Sponsor information unavailable

Signed by Governor

Drugs, Prescription

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Bill Overview

Analyzed Economic Effects

3 provisions identified: 0 benefits, 1 costs, 2 mixed.

Penalties for breaking health messaging rules

Employees or agents of state or local health agencies who break this law face discipline, including possible job loss. An entity that gets state grants, state-run federal funds, or other state inducements can be fined the greater of three times the misused state resources or $50,000. The attorney general can also bar that entity from receiving grants or inducements for 1 to 10 years, based on the severity of the violation.

Oversight and cleanup for state health messages

The commissioner and governor’s office must set an internal review to check messages against FDA labels by July 1, 2025. They must file a yearly compliance report starting January 15, 2026. The attorney general must set up a way to receive and investigate violation reports by July 1, 2025, and any person in Tennessee can report a suspected violation. After written notice of a violation, the entity has 10 days to stop the message and send a correction to the same audience. All covered groups must start removing noncompliant materials by July 1, 2025 and finish by January 15, 2026.

State health messages must match FDA labels

State health agencies and the governor’s office cannot share or fund messages about vaccines, masks, or emergency-use products that conflict with FDA labeling. They also cannot imply products are safe or effective to use together unless adequately powered, well-controlled trials support it. When a message talks about a product type in general, it must be true for all products in that group or clearly note the exceptions on specific labels. If state officials refer you to an outside source, the referral must say that source is not regulated by this law. The law still lets state leaders publicly criticize or disagree with FDA decisions.

Sponsors & Cosponsors

Sponsors

There is no primary sponsor on record.

Cosponsors

There are no cosponsors for this bill.

Roll Call Votes

All Roll Calls

Yes: 120 • No: 31

Senate vote • 3/17/2025

FLOOR VOTE: Third Consideration 3/17/2025

Yes: 26 • No: 6

House vote • 3/17/2025

FLOOR VOTE: REGULAR CALENDAR AS AMENDED PASSAGE ON THIRD CONSIDERATION 3/17/2025

Yes: 77 • No: 17

House vote • 3/17/2025

HOUSE CALENDAR & RULES COMMITTEE

Yes: 0 • No: 0

House vote • 3/11/2025

HOUSE HEALTH COMMITTEE

Yes: 11 • No: 6

House vote • 2/26/2025

HOUSE HEALTH SUBCOMMITTEE

Yes: 6 • No: 2

Bill Text

  • HA0069

    3/17/2025

  • Enrolled / Public Chapter

  • Fiscal Note

  • Introduced

  • SA0078

  • SA0079

Related Bills

Back to State Legislation